City of Hope enters product license agreement with ProBioGen AG for COVID vaccine manufacturing

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

City of Hope and ProBioGen AG have entered into a commercial product license agreement, which grants City of Hope the rights to use ProBioGen’s cell line AGE1.CR.pIX for manufacturing City of Hope’s COVID-19 vaccine candidate. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login